Updating results

Superior rectal artery embolisation for haemorrhoids (IPG627)

Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults

Interventional procedures guidance Published August 2018

Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias (an inserted device to help the heart beat at a normal rate)

Interventional procedures guidance Published August 2018

Sutureless aortic valve replacement for aortic stenosis (IPG624)

Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults

Interventional procedures guidance Published August 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)

Interventional procedures guidance Published August 2018

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of delayed-union and non-union fractures

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (IPG622)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at high risk of non-healing

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (IPG621)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at low risk of non-healing in adults

Interventional procedures guidance Published July 2018

Transaxial interbody lumbosacral fusion for severe chronic low back pain (IPG620)

Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults

Interventional procedures guidance Published July 2018

Superior capsular augmentation for massive rotator cuff tears (IPG619)

Evidence-based recommendations on superior capsular augmentation for massive rotator cuff (shoulder) tears

Interventional procedures guidance Published July 2018

Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes

Diagnostics guidance Published July 2018

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

Evidence-based recommendations on niraparib (Zejula) for the possible treatment of ovarian, fallopian tube or peritoneal cancer in adults

Technology appraisal guidance Published July 2018

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Technology appraisal guidance Published July 2018

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) to treat multiple sclerosis in adults

Technology appraisal guidance Published June 2018

Laparoscopic ventral mesh rectopexy for internal rectal prolapse (IPG618)

Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults

Interventional procedures guidance Published June 2018

Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (IPG617)

Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults

Interventional procedures guidance Published June 2018

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Intranasal phototherapy for allergic rhinitis (IPG616)

Evidence-based recommendations on intranasal phototherapy to reduce inflammation inside the nose in allergic rhinitis in adults

Interventional procedures guidance Published June 2018

Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults

Technology appraisal guidance Published June 2018

Midostaurin for untreated acute myeloid leukaemia (TA523)

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published June 2018

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

Evidence-based recommendations on endoscopic bipolar radiofrequency ablation (heat energy) to treat biliary obstruction (bile duct blockage) caused by cancer

Interventional procedures guidance Published May 2018

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy (IPG615)

Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

Interventional procedures guidance Published May 2018

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy in adults

Technology appraisal guidance Published May 2018

Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (IPG613)

Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis

Interventional procedures guidance Published May 2018

Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy

Diagnostics guidance Published April 2018

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Technology appraisal guidance Published April 2018

Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)

Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent (tube) for primary open-angle glaucoma in adults

Interventional procedures guidance Published April 2018

Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG611)

Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults

Interventional procedures guidance Published April 2018

Nerve transfer to partially restore upper limb function in tetraplegia (IPG610)

Evidence-based recommendations on nerve transfer to partially restore upper limb function in people with tetraplegia (quadriplegia; paralysis of arms and legs)

Interventional procedures guidance Published April 2018

Robot-assisted kidney transplant (IPG609)

Evidence-based recommendations on robot-assisted kidney transplant in adults

Interventional procedures guidance Published April 2018

Tocilizumab for treating giant cell arteritis (TA518)

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Technology appraisal guidance Published April 2018

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults

Technology appraisal guidance Published April 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Otitis media (acute): antimicrobial prescribing (NG91)

This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

Antimicrobial prescribing guideline Published March 2018

Thopaz+ portable digital system for managing chest drains (MTG37)

Evidence-based recommendations on Thopaz+ for people who need chest drainage after a pulmonary resection or because of a collapsed lung

Medical technologies guidance Published March 2018

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

This guidance has been updated and replaced by NICE technology appraisal guidance 555.

Technology appraisal guidance Published March 2018